Form 4: Nurix Therapeutics' Chief Legal Officer, Christine Ring, Executes Stock Option and Sells Shares Under 10b5-1 Plan

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan on January 2, 2025.

Summary

• On January 2, 2025, Christine Ring, the Chief Legal Officer of Nurix Therapeutics, exercised stock options to acquire 5,760 shares of common stock at a price of $1.86 per share.
• Simultaneously, Ms. Ring sold 5,760 shares of Nurix Therapeutics' common stock at a weighted average price of $19.4956 per share, with prices ranging from $18.91 to $19.73.
• These transactions were executed under a pre-existing Rule 10b5-1 trading plan.
• Following these transactions, Ms. Ring directly owns 28,084 shares of common stock and 53,986 derivative securities (employee stock options).

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The transactions are part of a pre-arranged plan, suggesting no particular bullish or bearish sentiment.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to trade company stock.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The exercise of options and subsequent sale of shares is a typical wealth management strategy.

Comparison to Industry Standards

• Insider trading activity is closely monitored across the biotechnology industry, with companies like Amgen, Gilead Sciences, and Biogen facing similar scrutiny regarding executive stock transactions.
• Rule 10b5-1 trading plans are a common practice among executives in publicly traded companies to manage their stock holdings while avoiding accusations of insider trading, aligning with industry standards for compliance and transparency.
• The reporting requirements for insider transactions, as mandated by the SEC, ensure that such activities are transparent and accessible to investors, promoting fair market practices across the industry.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares in the open market.
• The exercise of stock options could have a dilutive effect on existing shareholders, although the number of shares involved is relatively small.

Key Dates